ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Epstein-Barr virus (EBV)"

  • 2022 American Transplant Congress

    Clinical Outcomes of Solid Organ Transplant (SOT) Patients with Epstein-Barr Virus-Driven (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study

    V. Dharnidharka1, D. Thirumalai2, U. Jaeger3, W. Zhao2, D. Dierickx4, P. Xun2, P. Minga5, A. Sawas6, N. Sadetsky7, P. Chauvet8, E. Sundaram9, A. Barlev7, H. Zimmermann10, R. U. Trappe10

    1Washington University School of Medicine/St Louis Children’s Hospital, St Louis, MO, 2Atara Biotherapeutics, Thousand Oaks, CA, 3Medical University of Vienna, Vienna, Austria, 4Universitair Ziekenhuis Leuven, Leuven, Belgium, 5Niguarda Ca’ Granda Hospital, Milan, Italy, 6Herbert Irving Comprehensive Cancer Center, Department of Medicine, CUMC, New York, NY, 7Atara Biotherapeutics, South San Francisco, CA, 8Service des Maladies du Sang, CHU Lille, Lille, France, 9Nashville Biosciences, Nashville, TN, 10DIAKO Bremen, Bremen, Germany

    *Purpose: EBV+ PTLD patients (pts) following SOT who fail rituximab + chemotherapy (CT) have poor outcomes with limited treatment options. Published data on clinical outcomes…
  • 2022 American Transplant Congress

    EBV+ PTLD Tumor MicroRNAs Detected in Circulating Extracellular Vesicles Are Decreased in Pediatric Transplant Recipients with EBV+ PTLD

    A. Sen1, J. Enriquez1, M. Rao1, M. Glass1, Y. Balachandran1, S. Syed1, C. Twist1, K. Weinberg1, S. D. Boyd1, D. Bernstein1, A. Trickey1, D. Gratzinger1, B. Tan1, M. G. Lapasaran1, M. A. Robien2, M. Brown3, B. Armstrong4, M. Sever4, D. Desai5, G. Mazariegos6, C. Chin7, T. Fishbein8, R. S. Venick9, A. Tekin10, H. Zimmermann11, R. U. Trappe12, C. O. Esquivel1, O. M. Martinez1, S. M. Krams1

    1Stanford U, Palo Alto, CA, 2NIH, Bethesda, MD, 3NIAID, Bethesda, MD, 4Rho, Durham, NC, 5UT Southwestern, Dallas, TX, 6Pittsburgh U, Pittsburgh, PA, 7CCHMC, Cincinnati, OH, 8Georgetown U, Washington, DC, 9UCLA, LA, CA, 10Miami U, Miami, FL, 11DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany, 12Charité - Universitätsmedizin, Berlin, Germany

    *Purpose: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. Predisposing factors for PTLD include primary Epstein-Barr virus (EBV) infection in children,…
  • 2022 American Transplant Congress

    Pre-Emptive Rituximab to Prevent Post Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Kidney Transplant Recipients with EBV DNAemia: A Case Series from the Pediatric Nephrology Research Consortium (PNRC)

    I. Ashoor1, S. Ranabothu2, S. Al-Akash3, A. Moudgil4, Y. Shi4, S. Kizilbash5, D. Puliyanda6, V. Dharnidharka7

    1LSU Health Sciences Center New Orleans, New Orleans, LA, 2Arkansas Children's Hospital, Little Rock, AR, 3Driscoll Children's Hospital, Corpus Christie, TX, 4Children's National Medical Center, Washington, DC, 5University of Minnesota Medical Center, Minneapolis, MN, 6Cedars-Sinai Medical Center, Los Angeles, CA, 7Washington University in St. Louis, St Louis, MO

    *Purpose: The use of Rituximab (RTX) to prevent PTLD in patients with EBV DNAemia is an established strategy in hematopoietic stem cell transplants, but with…
  • 2022 American Transplant Congress

    PTLD Suspected by Visualization of Atypical Urinary Lymphocytes

    J. Huidobro E1, F. Anghileri2, P. Troncoso3, A. Huete4, P. Downey1

    1Nephrology, Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Clinical Laboratories, Pontificia Universidad Catolica de Chile, Santiago, Chile, 3Urology, Pontificia Universidad Catolica de Chile, Santiago, Chile, 4Radiology, Pontificia Universidad Catolica de Chile, Santiago, Chile

    *Purpose: Urinalysis has been used for the detection of acute rejection but visualization of atypical lymphocytes in the urine sediment as an early sign of…
  • 2022 American Transplant Congress

    Pre-Emptive Rituximab Use for Epstein-Barr Virus (EBV) Viremia in Cardiothoracic Solid Organ Transplant Recipients

    B. Astorga, A. Loethen, L. Potter

    University of Chicago Medicine, Chicago, IL

    *Purpose: EBV viremia is associated with potentially life-threatening post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. The utility of rituximab for treating EBV viremia in…
  • 2022 American Transplant Congress

    Use of Targeted T-Cell Therapy (Posoleucel) for the Treatment of Epstein-Barr Virus Associated Leiomyosarcoma in an Adult Kidney Transplant Recipient: A Case Report

    R. Saranu1, S. Nikiforow2, V. Jo3, H. So2, P. Stowe2, S. Tripathi1, F. Cardarelli4, A. Chandraker1

    1Renal Division, Brigham and Women's Hospital, Boston, MA, 2Dana Farber Cancer Institute, Boston, MA, 3Pathology, Brigham and Women's Hospital, Boston, MA, 4Allovir, Cambridge, MA

    *Purpose: Epstein-Barr virus (EBV)-associated leiomyosarcomas (EBV+LMS) are neoplasms rarely seen in solid organ transplant (SOT) recipients and currently lack effective treatment options. We present a…
  • 2022 American Transplant Congress

    Combined Metagenomic Viral Detection and Donor-Derived Cell-Free DNA Quantification for Solid Organ Transplant Recipients

    R. Sinha1, C. Rebello2, E. Bixler1, A. Al-Turck1, A. Berg1, J. Friedewald2, S. Kleiboeker1

    1Eurofins Viracor, Lees Summit, MO, 2Northwestern University, Chicago, IL

    *Purpose: Solid organ transplant recipients are predisposed to opportunistic infections, and current viral diagnostic methods focus on sensitive detection of single pathogens by qPCR. However,…
  • 2022 American Transplant Congress

    Post Transplant Virologic Outcomes in DCD Kidney Transplant Recipients Treated with Thymoglobulin Induction Immunosuppression and Maintenance Belatacept vs Calcineurin Inhibitor Therapy

    T. Engebretsen1, M. Kueht1, A. Lea2, M. Mujtaba3

    1Abdominal Transplant Surgery, University of Texas Medical Branch, Galveston, TX, 2Infectious Disease, University of Texas Medical Branch, Galveston, TX, 3Nephrology, University of Texas Medical Branch, Galveston, TX

    *Purpose: Belatacept is an inhibitor of the T-Cell costimulatory pathway that can be used in recipients of Donation after Circulatory Death (DCD) where the intended…
  • 2021 American Transplant Congress

    T-Cell Exhaustion in EBV DNAemic Solid Organ Transplant Recipients

    S. Kothari, T. Ku, D. Kumar, A. Humar, V. H. Ferreira

    Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada

    *Purpose: In transplant recipients, disease severity after infection with Epstein-Barr virus (EBV) may range from asymptomatic DNAemia to PTLD. Host factors likely play a key…
  • 2021 American Transplant Congress

    Gain of Function Mutations in Latent Membrane Protein 1 of Epstein Barr Virus are Associated with Increased Risk of Post-Transplant Lymphoproliferative Disorder

    O. M. Martinez1, S. M. Krams1, M. Robien2, M. Lapasaran1, M. Arvedson1, K. Weinberg1, S. Boyd1, B. Armstrong3, C. Twist4, D. Gratzinger1, B. Tan1, A. Trickey1, M. Sever3, M. Brown2, D. Bernstein1, C. O. Esquivel1

    1Stanford University Sch of Med, Stanford, CA, 2NIAID, Rockville, MD, 3Rho, Durham, NC, 4Roswell Park, Buffalo, NY

    *Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. Clinical Trials of Organ Transplantation in Children (CTOTC)-06 is a prospective…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences